Double drug combo offers hope for migraine sufferers
NCT ID NCT05653986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested how well two approved migraine medications, ubrogepant (for acute attacks) and atogepant (for prevention), work together in real-world settings. 391 adults with migraine used both drugs as prescribed by their doctor for 30 days. The goal was to see if the combination helped people get meaningful pain relief and return to normal daily activities faster.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore/Albert Einstein /ID# 252243
The Bronx, New York, 10461, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?